Acrodose™ Platelet: Whole Blood Derived Platelets, Pooled
|Safety | Efficiency | Availability
Acrodose Systems make use of the abundant supply of whole blood platelets that are more readily available than apheresis platelets. As a result, blood centers can expect increased product availability, fewer product shortages, and less need to import. An Acrodose Platelet offers a safe, efficient, and a readily-available alternative in platelet transfusion safety.
An Acrodose Platelet is a new platelet product that provides both blood centers and hospitals with a low-cost alternative to traditional whole blood derived (WBD) platests, as well as apheresis platelets.
Acrodose Platelets are:
- Not random donor platelets. An Acrodose Platelet is transfusion-ready for the hospital, as it is pooled, leukoreduced, ABO matched, and culture based tested for bacteria while also meeting AABB Interim Standard 220.127.116.11.1 for bacteria detection.
- And they are not a single donor platelet. An Acrodose Platelet provides a therapeutic dose of platelets equivalent to a single donor platelet, but typically at a lower cost.
Platelet Supply vs. Increasing Demand
Today many healthcare organizations are facing growing pressure to reduce costs, while maintaining or increasing their platelet supply due to the increasing demand for platelets. In many parts of the USA, apheresis platelets have become the standard of care. However, reliance on costly apheresis platelets has led to product shortages, especially during periods such as weekends and holidays. Further compounding the problem are continuing restrictions on donor acceptance*, making it even more difficult to maintain the blood supply.
*AABB Bulletin 06-07: AABB issued guidelines restricting use of previously pregnant female donors from donating "high plasma volume" blood products such as apheresis platelets. Whole blood-derived platelets are defined by the most recent AABB bulletin as a "lower plasma volume component" and "the per-unit risk attributed to antibody-mediated TRALI from [this] component appears to be significantly lower."